Discordance in 21-gene recurrence scores between paired breast cancer samples is inversely associated with patient age.

Background: The Oncotype DX 21-gene Recurrence Score is a genomic-based algorithm that guides adjuvant chemotherapy treatment decisions for women with early-stage, oestrogen receptor (ER)-positive breast cancer. However, there are age-related differences in chemotherapy benefit for women with interm...

Descripción completa

Detalles Bibliográficos
Publicado en:Breast Cancer Research Vol. 22; no. 1
Autores principales: Bernhardt, Sarah M., Dasari, Pallave, Wrin, Joseph, Raymond, Wendy, Edwards, Suzanne, Walsh, David, Townsend, Amanda R., Price, Timothy J., Ingman, Wendy V.
Formato: research Journal Article
Publicado: BioMed Central 8/18/2020
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=145259200&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 145259200
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        14655411
        8UYJ
      jtl: Breast Cancer Research
      issn: 14655411
      maglogo: N
    pubinfo:
      dt: 8/18/2020
      vid: 22
      iid: 1
      pid: 24147
      pub: BioMed Central
    artinfo:
      ui:
        145259200
        145259200
        NLM32811558
        145259200
        10.1186/s13058-020-01327-1
        NLM32811558
        145259200
      ppct: 1
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Discordance in 21-gene recurrence scores between paired breast cancer samples is inversely associated with patient age.
      aug:
        au:
          Bernhardt, Sarah M.
          Dasari, Pallave
          Wrin, Joseph
          Raymond, Wendy
          Edwards, Suzanne
          Walsh, David
          Townsend, Amanda R.
          Price, Timothy J.
          Ingman, Wendy V.
        affil: Discipline of Surgery, Adelaide Medical School, University of Adelaide, The Queen Elizabeth Hospital DX465702, 28 Woodville Rd, Woodville, 5011, Adelaide, Australia
      sug:
        subj:
          Breast Neoplasms Pathology
          Neoplasm Recurrence, Local Pathology
          Genetic Screening Methods
          Gene Expression Profiling Methods
          Neoplasm Recurrence, Local
          Breast Neoplasms
          Prognosis
          Aged
          Chemotherapy, Adjuvant
          Reproducibility of Results
          Neoplasm Recurrence, Local Drug Therapy
          Human
          Female
          Middle Age
          Breast Neoplasms Drug Therapy
          Age Factors
          Adult
          Validation Studies
          Comparative Studies
          Evaluation Research
          Multicenter Studies
          Aged: 65+ years
          Middle Aged: 45-64 years
          Adult: 19-44 years
          Female
      ab: Background: The Oncotype DX 21-gene Recurrence Score is a genomic-based algorithm that guides adjuvant chemotherapy treatment decisions for women with early-stage, oestrogen receptor (ER)-positive breast cancer. However, there are age-related differences in chemotherapy benefit for women with intermediate Oncotype DX Recurrence Scores that are not well understood. Menstrual cycling in younger women is associated with hormonal fluctuations that might affect the expression of genomic predictive biomarkers and alter Recurrence Scores. Here, we use paired human breast cancer samples to demonstrate that the clinically employed Oncotype DX algorithm is critically affected by patient age.Methods: RNA was extracted from 25 pairs of formalin-fixed paraffin-embedded, invasive ER-positive breast cancer samples that had been collected approximately 2 weeks apart. A 21-gene signature analogous to the Oncotype DX platform was assessed through quantitative real-time PCR, and experimental recurrence scores were calculated using the Oncotype DX algorithm.Results: There was a significant inverse association between patient age and discordance in the recurrence score. For every 1-year decrease in age, discordance in recurrence scores between paired samples increased by 0.08 units (95% CI - 0.14, - 0.01; p = 0.017). Discordance in recurrence scores for women under the age of 50 was driven primarily by proliferation- and HER2-associated genes.Conclusion: The Oncotype DX 21-gene Recurrence Score algorithm is critically affected by patient age. These findings emphasise the need for the consideration of patient age, particularly for women younger than 50, in the development and application of genomic-based algorithms for breast cancer care.
      pubtype: Academic Journal
      doctype:
        research
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N